Search Result
Results for "
ADC drug-linker
" in MedChemExpress (MCE) Product Catalog:
4
Biochemical Assay Reagents
4
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-156755
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Propargyl-PEG4-GGFG-DXd is a drug-linker conjugate for ADC. Propargyl-PEG4-GGFG-DXd contains a ADC linker and a DNA topoisomerase I inhibitor DXd (HY-13631D) .
|
-
-
- HY-156758
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Mal-PEG8-Val-Cit-PAB-MMAF is a drug-linker conjugate for ADC. Mal-PEG8-Val-Cit-PAB-MMAF contains a cleavable ADC linker and a potent tubulin inhibitor MMAE (HY-15162) .
|
-
-
- HY-13631O
-
-
-
- HY-157079
-
-
-
- HY-153428
-
-
-
- HY-164837
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
VcMMAE-Eribulin is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule MMAE (HY-15162) (Microtubule inhibitor) and Eribulin (HY-13442) (Microtubule inhibitor). VcMMAE-Eribulin can be used for ADC synthesis.
|
-
-
- HY-164835
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
VcMMAE-Deruxtecan is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule MMAE (HY-15162) (Microtubule inhibitor) and Exatecan (HY-13631) (DNA topoisomerase I inhibitor). VcMMAE-Deruxtecan can be used for ADC synthesis.
|
-
-
- HY-164836
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Deruxtecan-Eribulin is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule Exatecan (HY-13631) (DNA topoisomerase I inhibitor) and Eribulin (HY-13442) (Microtubule inhibitor). Deruxtecan-Eribulin can be used for ADC synthesis.
|
-
-
- HY-164788
-
-
-
- HY-153976
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Fmoc-Gly3-VC-PAB-MMAE is a Drug-Linker Conjugates for ADC. Fmoc-Gly3-VC-PAB-MMAE consists of Monomethyl auristatin E (HY-15162) and a linker .
|
-
-
- HY-154915
-
-
-
- HY-168285
-
-
-
- HY-156377
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Biotin-PEG7-Maleimide is a biotinylation reagent that reacts with thiol groups (SH). Biotin-PEG7-Maleimide can be used as Drug-Linker Conjugates for ADCs .
|
-
-
- HY-164309
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
DBCO-PEG3-Glu-Val-Cit-PABC-MMAE is a drug-linker conjugate for ADC. DBCO-PEG3-Glu-Val-Cit-PABC-MMAE contains a potent tubulin inhibitor Monomethyl auristatin E (MMAE, HY-15162) and can be used for synthesis of dual-drug ADC .
|
-
-
- HY-164829
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Mal-C5-Gly-Gly-Phe-MMAE (Compound S5) is a drug-linker conjugate for ADC. Mal-C5-Gly-Gly-Phe-MMAE consists of MMAE (HY-15162) and a linker. Mal-C5-Gly-Gly-Phe-MMAE can be used for synthesis of ADCs and for cancer research .
|
-
-
- HY-164792
-
-
-
- HY-157465
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
MA-PEG4-VC-PAB-DMEA-duocarmycin DM is a drug-linker conjugate for ADC by using the DNA minor-groove alkylator Duocarmycin DM (HY-130978), linked via MA-PEG4-vc-PAB-DMEA (HY-126668).
|
-
-
- HY-164239
-
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
|
Cancer
|
NH2-PEG3-VC-PAB-MMAE is a drug-linker conjugate for ADC, consisting of a cleavable ADC linker (NH2-PEG3-VC-PAB) and a potent tubulin inhibitor Monomethyl auristatin E (MMAE) (HY-15162). NH2-PEG3-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
-
- HY-163487
-
AZD8205 drug-linker
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Puxitatug samrotecan drug-linker (AZD8205 drug-linker) is part of the anti-B7-H4 antibody-conjugated active molecule ADC (drug-linker conjugate for ADC). Puxitatug samrotecan drug-linker contains a degradable ADC linker and a topoisomerase I inhibitor Exatecan (HY-13631) .
|
-
-
- HY-19813A
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
mDPR-Val-Cit-PAB-MMAE TFA is a drug-linker conjugate for ADC (Drug-Linker Conjugates for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and an ADC linker (peptide Val-Cit- PAB) composition [1] .
|
-
-
- HY-155870
-
-
-
- HY-155870A
-
-
-
- HY-148399
-
-
-
- HY-19697
-
-
-
- HY-160967
-
-
-
- HY-131451
-
-
-
- HY-45672
-
|
ADC Linker
|
Cancer
|
Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is an ADC Linker that can be used to synthesize Drug-Linker Conjugates for ADC. Especially for the synthesis of Deruxtecan (HY-13631E), a toxic drug-linker conjugate .
|
-
-
- HY-164705
-
-
-
- HY-164707
-
-
-
- HY-168550
-
|
ADC Linker
|
Cancer
|
STI-8811 drug-linker is a linker for synthesis of ADC molecule STI-8811 .
|
-
-
- HY-128896
-
-
-
- HY-W190944
-
-
-
- HY-158349
-
-
-
- HY-153032
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Val-Ala-PAB-MMAE is a Drug-Linker Conjugate for ADC, consisting of ADC linker (Val-Ala-PAB) and MMAE. MMAE is an effective inhibitor of tubulin.
|
-
-
- HY-128959
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
MCC-Modified Daunorubicinol is a drug-Linker conjugates for ADC, which is composed of Modified Daunorubicinol (DNA topoisomerase II inhibitor) and MCC (ADC linker) linked .
|
-
-
- HY-169324
-
Mal-Exo-EEVC-Exatecan
|
Drug-Linker Conjugates for ADC
|
Cancer
|
APL-1092 (Mal-Exo-EEVC-Exatecan) is a drug-linker conjugate for ADC, which contains Exatecan (HY-13631) (ADC payload) and a linker .
|
-
-
- HY-153069
-
-
-
- HY-156687
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
GGFG-Eribulin (Compound GGFG) is a Drug-Linker Conjugates for ADC. GGFG-Eribulin consists of the ADC Cytotoxin Eribulin (HY-13442) and a linker. GGFG-Eribulin can be used for synthesis of ADCs .
|
-
-
- HY-158348
-
-
-
- HY-157284
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Cys-mc-MMAE is a Drug-Linker Conjugates for ADC, and consists of Monomethyl auristatin E (HY-15162) and a linker. Cys-mc-MMAE can be used for synthesis of ADCs .
|
-
-
- HY-157407
-
-
-
- HY-164706
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
m-PEG6-Lys-Mal-Toxophore-quinoline is a drug-linker conjugate for ADC and can be used for ADC synthesis. The payload is a NAMPT inhibitor (HY-164760) .
|
-
-
- HY-78738
-
|
ADC Linker
|
Cancer
|
MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.
|
-
-
- HY-49929
-
|
ADC Linker
|
Cancer
|
MC-GGFG-NH-CH2-O-CH2-cyclopropane-COOH is an ADC linker that can be combined with the cytotoxic Camptothecin (HY-16560) to form ADC-related drug-linker conjugates (Drug-Linker Conjugates for ADC ).MC-GGFG-NH-CH2-O-CH2-cyclopropane-COOH is conjugated to Camptothecin, which can further bind to the antibody Trastuzumab (HY-P9907) to form Antibody-Drug Conjugates (ADCs) .
|
-
-
- HY-136313
-
-
-
- HY-158351
-
-
-
- HY-156848
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Fmoc-GGFG-DXd is a drug-linker conjugate for ADC. Fmoc-GGFG-DXd contains a ADC linker Fmoc-GGFG and a DNA topoisomerase I inhibitor DXd (HY-13631D) .
|
-
-
- HY-15575G
-
MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE
|
Drug-Linker Conjugates for ADC
|
Cancer
|
VcMMAE (MC-Val-Cit-PAB-MMAE) (GMP) is VcMMAE (HY-15575) produced by using GMP guidelines. VcMMAE is a drug-linker conjugate for ADC .
|
-
-
- HY-W250408
-
-
-
- HY-153909
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
SMP-33693 is a Drug-Linker Conjugate for ADC with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .
|
-
- HY-153601
-
|
Drug-Linker Conjugates for ADC
DNA/RNA Synthesis
|
Cancer
|
MC-VC-PAB-Cyclohexanediamine-Thailanstatin A is a Spliceostatin (HY-16466) analog, and a drug-linker conjugates for ADC, consisting of ADC Cytotoxin Thailanstatin A (HY-129589) and cleavable ADC linker (MC-vc-PAB). MC-VC-PAB-Cyclohexanediamine-Thailanstatin A can be used for ADC synthesis .
|
-
- HY-13631E
-
Deruxtecan
Maximum Cited Publications
9 Publications Verification
MC-GGFG-DXD
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a
maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
|
-
- HY-160807
-
-
- HY-158137
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Val-Cit-PAB-DEA-Dxd (compound 81) is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule Dxd (DNA topoisomerase I inhibitor). Val-Cit-PAB-DEA-Dxd can be used for ADC synthesis .
|
-
- HY-153345
-
-
- HY-137883
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Br is a drug-linker conjugate for ADC that can be used to synthesize ABBV-154, ABBV-927, ABBV-368 or their analogs .
|
-
- HY-153395
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
PH-HG-005-5 (compound 16c) is a derivative of SN-38 (HY-13704) and can be used as Drug-Linker Conjugates for ADC. PH-HG-005-5 can conjugate to targeting peptides for ADCs synthesis .
|
-
- HY-W591408
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
DBCO-Val-Cit-PAB-MMAE is a drug-linker conjugate, which can be used for the synthesis of ADC molecules. MMAE (HY-15162) is a tubulin inhibitor, which can be used as an ADC toxin. DBCO-Val-Cit-PAB is the linker with the electrophilic group .
|
-
- HY-160015
-
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
CB07-Exatecan is an ADC drug-Linker conjugate that can be used for the synthesis of ADCs. ADC conjugated with CB07-Exatecan and trastuzumab inhibits the growth of HER2-positive cancer cells. CB07-Exatecan can be used in cancer research .
|
-
- HY-147095
-
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
Val-Ala-PABC-Exatecan is a Drug-Linker Conjugates for ADC,consiting of a cleavable Tesirine linker (Val-Ala-PABC) and Exatecan (topoisomerase I inhibitor,HY-13631). Val-Ala-PABC-Exatecan can be used for ADC molecues synthesis,such as Mal-PEGn-amide-va-Exatecan .
|
-
- HY-160788
-
-
- HY-45672G
-
|
ADC Linker
|
Cancer
|
Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH GMP is a GMP grade Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (HY-45672). Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is an ADC Linker that can be used to synthesize Drug-Linker Conjugates for ADC. Especially for the synthesis of Deruxtecan (HY-13631E), a toxic drug-linker conjugate .
|
-
- HY-147095A
-
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
Val-Ala-PABC-Exatecan trifluoroacetate is a Drug-Linker Conjugates for ADC, consiting of a cleavable Tesirine linker (Val-Ala-PABC) and Exatecan (topoisomerase I inhibitor, HY-13631). Val-Ala-PABC-Exatecan trifluoroacetate can be used for ADC molecues synthesis, such as Mal-PEGn-amide-va-Exatecan .
|
-
- HY-W731085
-
|
ADC Linker
|
Cancer
|
MC-GGFG-NH-CH2-O-CH2-(s-cyclopropane)-COOH is an ADC linker that can be combined with the cytotoxic Camptothecin (HY-16560) to form an ADC-related drug-linker conjugate (Drug- Linker Conjugates for ADC).MC-GGFG-NH-CH2-O-CH2-cyclopropane-COOH is conjugated to Camptothecin, which can further bind to the antibody Trastuzumab (HY-P9907) to form Antibody-Drug Conjugates (ADCs) .
|
-
- HY-164303
-
-
- HY-160885
-
|
ADC Cytotoxin
|
Others
|
NH2-Gly-PAB-Exatecan-D-glucuronic acid (Compound 8) is an intermediate, which reacts with NHS group to form drug-linker conjugate for ADC, Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179) .
|
-
- HY-145989S
-
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
|
Cancer
|
Aminobenzenesulfonic auristatin E-d8 is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic[1][2].
|
-
- HY-78738G
-
|
ADC Linker
|
Cancer
|
MC-Val-Cit-PAB GMP is a GMP grade MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.
|
-
- HY-128910
-
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
|
Cancer
|
MC-VC(S)-PABQ-Tubulysin M is a synthetic ADC drug-linker conjugate composed of the tubulin polymerization inhibitor Tubulysin M (an ADC Cytotoxin) (HY-N7053) and MC-VC(S)- PABQ (an ADC linker) is connected. MC-VC(S)-PABQ-Tubulysin M is effective against multidrug-resistant lymphoma cell lines and tumors .
|
-
- HY-158199
-
|
ADC Linker
|
Cancer
|
BCN-HS-PEG2-bis(PNP) (Compound 62) is a p-nitrophenyl-containing ADC linker that can be used to further couple ADC cytotoxins with peptide linkers. BCN-HS-PEG2-bis(PNP) can conjugate with vc-PABC-MMAE (HY-15162) to form Drug-Linker Conjugates for ADC .
|
-
- HY-164153
-
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
ADC Control Human IgG1-vcMMAE is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
|
-
- HY-164669
-
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
ADC Control Human IgG1-DM4 is an isotype control of ADC Human IgG1-DM4. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is SPDB-DM4 (HY-12460).
|
-
- HY-153263
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
(Aminooxy)acetamide-Val-Cit-PAB-MMAE (MMAE 5) is an intermediate used in the synthetic preparation of drug-linker conjugates for ADC. (Aminooxy)acetamide-Val-Cit-PAB-MMAE is conjugated to polyamide via oxime bond formation to form MMAE polyamide conjugate. Then MMAE polyamide conjugate can be conjugated to Trastuzumab, to make ADC .
|
-
- HY-158768
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Amino-PEG4-GGFG-Dxd (Compound 13-7) is a drug-linker conjugate for ADC. Amino-PEG4-GGFG-Dxd is composed of Dxd (HY-13631D) and a linker. Amino-PEG4-GGFG-Dxd can be used for synthesis of ADCs
|
-
- HY-164088
-
-
- HY-160893
-
|
Drug-Linker Conjugates for ADC
PSMA
|
Cancer
|
PSMA-Val-Cit-PAB-Azide is a drug-linker conjugate for ADC. PSMA-Val-Cit-PAB-Azide contains the cleavable ADCs linker (Val-Cit-PAB) and a novel small-molecule PSMA-targeted conjugate. It contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups .
|
-
- HY-164152
-
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
|
Cancer
|
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
-
- HY-164154
-
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
|
-
- HY-164152A
-
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
|
Cancer
|
ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
-
- HY-13631ES4
-
-
- HY-13631ES
-
-
- HY-153795
-
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan is a drug-linker conjugate for ADC. Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan consists of Exatecan (HY-13631) and a linker. Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan can be used for synthesis of ADCs and for cancer research .
|
-
- HY-112786
-
Vc-MMAF
|
Drug-Linker Conjugates for ADC
|
Cancer
|
MC-Val-Cit-PAB-MMAF (Vc-MMAF) is a drug-linker conjugate for ADC by using the tubulin inhibitor, MMAF (HY-15579), linked via cathepsin cleavable MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB-MMAF shows antitumor activity .
|
-
- HY-157465A
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
MA-PEG4-VC-PAB-DMEA-duocarmycin DM TFA is a drug-linker conjugate for ADC by using the DNA minor-groove alkylator Duocarmycin DM (HY-130978), linked via MA-PEG4-vc-PAB-DMEA (HY-126668).
|
-
- HY-141147
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
7-O-(Amino-PEG4)-paclitaxel is a PEG-class Drug-linker conjugates for ADC, containing a paclitaxel moiety and a amino group. The amine group is reactive with carboxylic acids, activated NHS esters, carbonyls (ketone, aldehyde) etc. 7-O-(Amino-PEG4)-paclitaxel can be used in the synthesis of Antibody-Drug Conjugates (ADCs) .
|
-
- HY-400878
-
|
Glucocorticoid Receptor
Drug-Linker Conjugates for ADC
|
Cancer
|
Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Mal, a glucocorticoid receptor agonist, is a drug-linker conjugate for ADC. Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Mal can be used to synthesize the anti-CD40 antibody agent conjugates (WO2019106608A1; example 9) .
|
-
- HY-156691
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
TLR7/8 agonist 4 hydroxy-PEG6-acid is a Drug-Linker Conjugates for ADC. TLR7/8 agonist 4 hydroxy-PEG6-acid consists of TLR7/8 agonist 4 (HY-139017) and a linker Hydroxy-PEG6-acid (HY-133050), and can be used for synthesis of ADCs .
|
-
- HY-141148
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
7-O-(Cbz-N-amido-PEG4)-paclitaxel is a PEG-class Drug-linker conjugates for ADC, containing a paclitaxel moiety and a amino group. The amine group is reactive with carboxylic acids, activated NHS esters, carbonyls (ketone, aldehyde) etc. 7-O-(Cbz-N-amido-PEG4)-paclitaxel can be used in the synthesis of Antibody-Drug Conjugates (ADCs) .
|
-
- HY-145399
-
SG 3932
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan is a Drug-Linker Conjugates for ADC, which comprises a topoisomerase inhibitor and a linker for ligand unit connecting. Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan can be used to synthesis antibody-drug conjugate (ADC) .
|
-
- HY-149416
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Mal-PEG8-Val-Ala-PAB-SB-743921 (Compound D7) is a Drug-Linker Conjugates for ADC. Mal-PEG8-Val-Ala-PAB-SB-743921 consists of KSP inhibitor SB-743921 (HY-14661) and a linker. Mal-PEG8-Val-Ala-PAB-SB-743921 can be used for synthesis of ADCs .
|
-
- HY-P990027
-
|
ADC Antibody
|
Cancer
|
Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C (a Drug-Linker Conjugates for ADC), to synthesize IMGC936 (Antibody-Drug Conjugates (ADCs)) with strong anti-cancer activity. DM21-C is composed of Maytansinoid (microtubule inhibitor) and a stable tripeptide linker. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models .
|
-
- HY-160234
-
|
ADC Linker
|
Cancer
|
mc-vc-PAB-PBD is a drug linker for the preparation of TDC and ADC .
|
-
- HY-160885A
-
|
ADC Cytotoxin
|
Cancer
|
NH2-Gly-PAB-Exatecan-D-glucuronic acid formic (Compound 8) is the formic salt form of H2N-Gly-PAB-Exatecan-D-glucuronic acid. H2N-Gly-PAB-Exatecan-D-glucuronic acid formic is an intermediate, which reacts with NHS group to form drug-linker conjugate for ADC, Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179) .
|
-
- HY-P4192
-
|
ADC Linker
|
Cancer
|
Fomc-Gly-Gly-Phe-Gly-OH (compound D5) can be used as an intermediate in the synthesis of ADC dual-drug-linker. Fomc-Gly-Gly-Phe-Gly-OH synthetic intermediate GGFGE further forms an important ADC dual-drug link assembly unit .
|
-
- HY-159563
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Mal-va-mac-SN38 is a drug-linker conjugate for ADC. Mal-va-mac-SN38 contains a ADC cytotoxin SN-38 (HY-13704) and a linker (HY-126364). Mal-va-mac-SN38 can rapidly and covalently bind with endogenous albumin in vivo, resulting in the formation of HSA-va-mac-SN38. Mal-va-mac-SN38 demonstrates exceptional stability in human plasma, and has anti-tumor and anti-metastasis effect .
|
-
- HY-400770
-
1-(2-Amino-4-fluoro-5-methylphenyl)-2-chloroethanone
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
MC-GGFG-AM-(10Me-11F-Camptothecin) intermediate-1 (compound 19-2) is an intermediate for the synthesis of MC-GGFG-AM-(10Me-11F-Camptothecin) (HY-153360). Modifying groups can be added group. MC-GGFG-AM-(10Me-11F-Camptothecin) is a drug-linker conjugate used in the synthesis of ADCs .
|
-
- HY-157813
-
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-Exatecan is a drug-linker conjugates for ADC, consiting of a cleavable linker and Exatecan (HY-13631). 2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-Exatecan can be linked to anti-Her3 antibody .
|
-
- HY-160899A
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Thailanstatin A cyclohexane diamine formic is an analog of Spliceostatin (HY-16466). Thailanstatin A cyclohexane diamine formic inhibits proliferations of cells N87 (IC50 is 0.33 μM), BT474 (IC50 is 0.34 μM), MDA-MB-361-DYT2 (IC50 is 0.88 μM) and MDA-MB-468 (IC50 is 0.27 μM). Thailanstatin A cyclohexane diamine formic is used as a drug-linker conjugate for ADC molecule .
|
-
- HY-156691A
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride is a Drug-Linker Conjugates for ADC. TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride is the hydrochloride form of TLR7/8 agonist 4 hydroxy-PEG6-acid. TLR7/8 agonist 4 hydroxy-PEG6-acid consists of TLR7/8 agonist 4 (HY-139017) and a linker Hydroxy-PEG6-acid (HY-133050), and can be used for synthesis of ADCs .
|
-
- HY-148875
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Py-MAA-Val-Cit-PAB-MMAE is a drug-Linker conjugates for ADC, which is composed of MMAE (HY-15162) and Py-MAA-Val-Cit-PAB linked. Py-MAA-Val-Cit-PAB-MMAE can be used to synthesize Zapadcine-3a, which targeting TRAILR2. Zapadcine-3a has broad-spectrum anti-tumor activity, and can specifically kill TRAILR2-positive tumors .
|
-
- HY-156515
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) (compound 141) is a drug-linker conjugates for ADC. MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) is a MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) with protease cleavable MC-GGFG linker .
|
-
- HY-153892
-
-
- HY-159668
-
|
ADC Linker
|
Cancer
|
DL002 is a ADC linker that can be used to synthesize antibody-drug conjugates containing BCL-2 family protein degraders, and it's used in tumor research .
|
-
- HY-111012
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
DBCO-(PEG)3-VC-PAB-MMAE is a agent-linker conjugate for ADC. DBCO-(PEG)3-VC-PAB-MMAE is made by Monomethyl auristatin E (HY-15162) conjugats to DBCO-(PEG)3-vc-PAB linker. DBCO-(PEG)3-VC-PAB-MMAE can be used for the research of cancer . DBCO-(PEG)3-VC-PAB-MMAE is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-148339
-
|
Drug-Linker Conjugates for ADC
|
Others
|
Fmoc-VAP-MMAE is a agent-linker conjugates for ADC. Fmoc-VAP-MMAE consists of an ADC linker and a tubulin inhibitor MMAE (HY-15162), with a protective Fmoc group .
|
-
- HY-15575S
-
MC-Val-Cit-PAB-MMAE-d8; mc-vc-PAB-MMAE-d8
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
|
Cancer
|
VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc) .
|
-
- HY-160143
-
-
- HY-153739
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
N3-PEG3-VC-PAB-MMAF (Comp T-88-5) is a drug-linker conjugate containing the ADC linker N3-PEG3-VC-PAB and the tubulin inhibitor MMAF . N3-PEG3-VC-PAB-MMAF is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-148820
-
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT (Formula V) is a agent-linker conjugate that composed of a potent topoisomerase I inhibitor and a linker to make antibody agent conjugate (ADC) .
|
-
- HY-135928
-
|
ADC Linker
|
Cancer
|
Biotin-C2-S-S-pyridine is a cleavable ADC linker. Biotin-C2-S-S-pyridine can be used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-160247
-
|
Drug-Linker Conjugates for ADC
|
Others
|
Boc-Lys-PEG8-N-bis(D-glucose) (compound 89-5) is a drug linker that can be used in the synthesis of antibody-drug conjugates (ADCs) extracted from patent WO2023280227A2 .
|
-
- HY-132252
-
MP-PEG8-Val-Ala-PABC; MP-PEG8-VA-PABC
|
ADC Linker
|
Cancer
|
Mal-PEG8-Val-Ala-PABC is a cleavable Tesirine linker used in the synthesis of Tesirine, a agent-linker conjugate for ADC .
|
-
- HY-132261
-
4-(4-Acetyl-phenoxy)-butyric acid
|
ADC Linker
|
Cancer
|
AcBut is a cleavable Ozogamicin linker used in the synthesis of Ozogamicin, a agent-linker conjugate for ADC .
|
-
- HY-13631F
-
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
Gly-Gly-Phe-Gly-NH-O-CO-Exatecan, as a drug-linker conjugate composed of linker Gly-Gly-Phe-Gly-NH-O-CO and Exatecan, can be used to prepare antibody conjugate drugs. Exatecan is a DNA topoisomerase I inhibitor that can be used in cancer research .
|
-
- HY-164637
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Aniline-PEG3-C1-Boc (compound D-1) is an intermediate of cytotoxic drug linker polymer. Aniline-PEG3-C1-Boc can be used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-153962
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 is a Drug-Linker Conjugate for ADC. SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 consists of the anti-cancer agent SN38 (HY-13704) and a linker Lys(MMT)-PAB-oxydiacetamide-PEG8-N3 (HY-131157). SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 can be used for synthesis of ADCs . SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-100566
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
SuO-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB .
|
-
- HY-136291
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Sulfo-SPDB-DGN462 is a agent-linker conjugate for ADC. Sulfo-SPDB-DGN462 consists a toxin DGN462 (HY-101150) conjugated to the cleavable Sulfo-SPDB linker. DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML).
|
-
- HY-148194
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
SC239 is a cleavable 2-aminophenyl hemiasterlin agent-linker. SC239 can be as the agent-linker for ADC . SC239 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
Cat. No. |
Product Name |
Type |
-
- HY-15575G
-
MC-Val-Cit-PAB-MMAE (GMP); mc-vc-PAB-MMAE (GMP)
|
Fluorescent Dye
|
VcMMAE (MC-Val-Cit-PAB-MMAE) (GMP) is VcMMAE (HY-15575) produced by using GMP guidelines. VcMMAE is a drug-linker conjugate for ADC .
|
-
- HY-45672G
-
|
Fluorescent Dye
|
Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH GMP is a GMP grade Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (HY-45672). Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is an ADC Linker that can be used to synthesize Drug-Linker Conjugates for ADC. Especially for the synthesis of Deruxtecan (HY-13631E), a toxic drug-linker conjugate .
|
-
- HY-78738G
-
|
Fluorescent Dye
|
MC-Val-Cit-PAB GMP is a GMP grade MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.
|
Cat. No. |
Product Name |
Type |
-
- HY-15575G
-
MC-Val-Cit-PAB-MMAE (GMP); mc-vc-PAB-MMAE (GMP)
|
Biochemical Assay Reagents
|
VcMMAE (MC-Val-Cit-PAB-MMAE) (GMP) is VcMMAE (HY-15575) produced by using GMP guidelines. VcMMAE is a drug-linker conjugate for ADC .
|
-
- HY-45672G
-
|
Biochemical Assay Reagents
|
Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH GMP is a GMP grade Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (HY-45672). Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is an ADC Linker that can be used to synthesize Drug-Linker Conjugates for ADC. Especially for the synthesis of Deruxtecan (HY-13631E), a toxic drug-linker conjugate .
|
-
- HY-78738G
-
|
Biochemical Assay Reagents
|
MC-Val-Cit-PAB GMP is a GMP grade MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.
|
-
- HY-135928
-
|
Biochemical Assay Reagents
|
Biotin-C2-S-S-pyridine is a cleavable ADC linker. Biotin-C2-S-S-pyridine can be used in the synthesis of antibody-drug conjugates (ADCs) .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P4192
-
|
ADC Linker
|
Cancer
|
Fomc-Gly-Gly-Phe-Gly-OH (compound D5) can be used as an intermediate in the synthesis of ADC dual-drug-linker. Fomc-Gly-Gly-Phe-Gly-OH synthetic intermediate GGFGE further forms an important ADC dual-drug link assembly unit .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-164153
-
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
ADC Control Human IgG1-vcMMAE is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
|
-
- HY-164152
-
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
|
Cancer
|
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
-
- HY-164154
-
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
|
-
- HY-P990027
-
|
ADC Antibody
|
Cancer
|
Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C (a Drug-Linker Conjugates for ADC), to synthesize IMGC936 (Antibody-Drug Conjugates (ADCs)) with strong anti-cancer activity. DM21-C is composed of Maytansinoid (microtubule inhibitor) and a stable tripeptide linker. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models .
|
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-145989S
-
|
Aminobenzenesulfonic auristatin E-d8 is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic[1][2].
|
-
-
- HY-13631ES4
-
|
Deruxtecan-d5 is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
|
-
-
- HY-13631ES
-
|
Deruxtecan-d4 is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
|
-
-
- HY-15575S
-
|
VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc) .
|
-
Cat. No. |
Product Name |
|
Classification |
-
- HY-157407
-
|
|
Alkynes
|
Cyclooctyne-O-amido-PEG4-VC-PAB-Gly-Gly-NH-O-CO-Exatecan is a drug-linker conjugate for ADC (ADC Cytotoxin: Exatecan) .
|
-
- HY-160893
-
|
|
Azide
|
PSMA-Val-Cit-PAB-Azide is a drug-linker conjugate for ADC. PSMA-Val-Cit-PAB-Azide contains the cleavable ADCs linker (Val-Cit-PAB) and a novel small-molecule PSMA-targeted conjugate. It contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups .
|
-
- HY-111012
-
|
|
DBCO
|
DBCO-(PEG)3-VC-PAB-MMAE is a agent-linker conjugate for ADC. DBCO-(PEG)3-VC-PAB-MMAE is made by Monomethyl auristatin E (HY-15162) conjugats to DBCO-(PEG)3-vc-PAB linker. DBCO-(PEG)3-VC-PAB-MMAE can be used for the research of cancer . DBCO-(PEG)3-VC-PAB-MMAE is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-153962
-
|
|
Azide
|
SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 is a Drug-Linker Conjugate for ADC. SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 consists of the anti-cancer agent SN38 (HY-13704) and a linker Lys(MMT)-PAB-oxydiacetamide-PEG8-N3 (HY-131157). SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 can be used for synthesis of ADCs . SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-148194
-
|
|
DBCO
|
SC239 is a cleavable 2-aminophenyl hemiasterlin agent-linker. SC239 can be as the agent-linker for ADC . SC239 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-164309
-
|
|
DBCO
|
DBCO-PEG3-Glu-Val-Cit-PABC-MMAE is a drug-linker conjugate for ADC. DBCO-PEG3-Glu-Val-Cit-PABC-MMAE contains a potent tubulin inhibitor Monomethyl auristatin E (MMAE, HY-15162) and can be used for synthesis of dual-drug ADC .
|
-
- HY-164792
-
|
|
DBCO
|
DBCO-PEG3-VC-Exatecan (compound 25) is a Drug-Linker Conjugate for ADC. DBCO-PEG3-VC-Exatecan contains the ADC linker (DBCO-PEG3-VC) and a DNA topoisomerase I inhibitor Exatecan (HY-13631) .
|
-
- HY-158199
-
|
|
BCN
|
BCN-HS-PEG2-bis(PNP) (Compound 62) is a p-nitrophenyl-containing ADC linker that can be used to further couple ADC cytotoxins with peptide linkers. BCN-HS-PEG2-bis(PNP) can conjugate with vc-PABC-MMAE (HY-15162) to form Drug-Linker Conjugates for ADC .
|
-
- HY-153739
-
|
|
Azide
|
N3-PEG3-VC-PAB-MMAF (Comp T-88-5) is a drug-linker conjugate containing the ADC linker N3-PEG3-VC-PAB and the tubulin inhibitor MMAF . N3-PEG3-VC-PAB-MMAF is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: